Maturity Onset Diabetes of the Young Clinical Trials

Find Maturity Onset Diabetes of the Young Clinical Trials Near You

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity

Status: Recruiting
Location: See all (27) locations...
Intervention Type: Device, Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the RESET System for Glycemic Improvement in Patients with Inadequately Controlled Type 2 Diabetes and Obesity, the STEP-1 Study. A multi-center, double-blinded, randomized, sham-controlled trial to evaluate the safety and effectiveness of the RESET System plus moderate intensity lifestyle and dietary counseling compliant with 2024 ADA Standard of Care as compared to a sham control receiving moderate intensity lifestyle and dietary counseling. Both the treatment and sham group will practice medical management compliant with STEP-1 Study Guidelines. Patients will be randomized 3 (RESET):1 (Sham).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 22
Maximum Age: 65
Healthy Volunteers: f
View:

• Age ≥22 years and ≤ 65 years

• Have understood and signed the approved informed consent form

• Diagnosis of type 2 diabetes

• HbA1c ≥ 7.5% and ≤10%

• BMI ≥30kg/m2 and ≤ 50kg/m2

• Willing and able to comply with study requirements

• Documented negative pregnancy test in women of childbearing potential

• Women of childbearing potential not intending to become pregnant (continue to be on an approved form of birth control) for the duration of their trial participation, including post explant period. Women of child-bearing age without known sterilization will be placed on 1 form of birth-control to prevent unwanted pregnancies

• At least one year of medical records available, including detailed medical therapy and dosing information

⁃ Failed to achieve adequate HbA1c reduction (\<7.5%) after dual therapy for at least 3-month stable dosage of diabetes medication(s), including insulin, metformin, SGLT-2 inhibitor, GLP-1 RA, Dual GLP-1/GIPR agonist or, other medications including meglitinides, sulfonylureas, thiazolidinediones, or DPP-4s.

Locations
United States
Arizona
Banner Health
RECRUITING
Gilbert
M3 Wake Research
RECRUITING
Tucson
Washington, D.c.
MedStar Health Research Institute
RECRUITING
Washington D.c.
Florida
Imagine Research
RECRUITING
Boynton Beach
HCA Health Research Institute
RECRUITING
Miami
UMiami
RECRUITING
Miami
Quantum Clinical Trials
RECRUITING
Miami Beach
Optimal Research Sites
RECRUITING
Orange City
Orlando Health
RECRUITING
Orlando
Denali Health Plant City
RECRUITING
Plant City
Clinical Research Center of Florida
RECRUITING
Pompano Beach
Health Synergy Clinical Research
NOT_YET_RECRUITING
West Palm Beach
Georgia
Denali Health Atlanta
RECRUITING
Atlanta
Drug Studies America
RECRUITING
Marietta
EBGS Clinical Research
RECRUITING
Snellville
Louisiana
Elevate Clinical Research, Lake Charles
RECRUITING
Lake Charles
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Michigan
Michigan Medicine, Division of Gastroenterology and Hepatology
RECRUITING
Ann Arbor
Minnesota
Mayo Clinic
RECRUITING
Rochester
New York
Weill Cornell Medicine
RECRUITING
New York
Texas
Elevate Clinical Research, Atascocita
RECRUITING
Atascocita
M3 Wake Research
RECRUITING
Dallas
Epic Medical Research
RECRUITING
Desoto
Care United Research
RECRUITING
Forney
Baylor College of Medicine
RECRUITING
Houston
Elevate Clinical Research, Houston
RECRUITING
Houston
VAST Clinical Research
RECRUITING
Prosper
Contact Information
Primary
Aoife Devery, MA
adevery@morphicmed.com
617.528.8880
Backup
Lina Ginneti, BS
lginnetti@morphicmed.com
617.216.6699
Time Frame
Start Date: 2019-09-09
Estimated Completion Date: 2029-09-30
Participants
Target number of participants: 264
Treatments
Experimental: RESET Treatment Arm
Patients in ARM 1, will receive an upper endoscopy and will be treated with the RESET Liner
Sham_comparator: Sham Control Arm
Patients in Arm 2 will receive an upper endoscopy, but will not be treated with the RESET Liner.
Sponsors
Collaborators: Biostatistical Consulting, Inc.
Leads: Morphic Medical Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials